2021 IPO

Celularity Stock

Biotechnology Company

Sign up today and learn more about Celularity Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Founded

2016

Notable Investors

Celgene

Headquarters

Warren NJ, US

Total Funding

$290M

About Celularity Stock

Celularity is a developer of therapies designed to treat autoimmune and degenerative diseases, immuno-oncology and functional regeneration. The company's therapies productize allogeneic cells and tissues derived from the postpartum placenta and have the ability to augment immunity and longevity by amplifying the body's ability to fight disease, heal and regenerate itself, enabling patients to begin treatment more quickly, resulting in a better medical outcome.

Investors

Celgene

Celularity

Human Longevity

Celularity

Sorrento Therapeutics

Celularity

United Therapeutics

Celularity

Funding History

August 2017$185M
August 2017$75.0M
May 2018$565M

Management

Chief Executive Officer

Robert Hariri

Chief Financial Officer

David Beers

Press

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo